PTH AGONISTS

This invention relates to compounds of formula (I) or (II) wherein, in either formula, independently; R1 and R2 are the same or are different and are C1-8 alkyl, C2-8 alkylene, C3-8 cycloalkyl, aryl, heteroaryl, heterocycloalkyl, C3-6 cycloalkylaryl, or heterocycloaryl; wherein said alkyl, alkylene, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylaryl, or heterocycloaryl are unsubstituted or substituted by one or more groups selected from the group consisting of halogen, C1-8 alkyl, C1-8alkoxy, C1-8thioalkoxy, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, CF3, SCF3, NHC(O)nR5, S(O)mR5, S(O)2NR5R6, C(S)NR5R6, CONR5R6, C(O)nR5; n is 0, 1 or 2; m is 0, 1 or 2; R5 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C1-8alkoxy, aryl, heteroaryl, halogen, NO2, CN, N3, SCF3, and CF3; R6 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C1-8alkoxy, aryl, heteroaryl, halogen, NO2, CN, N3, SCF3, and CF3, or when R1 and/or R2 contains S(O)2NR5R6, CONR5R6, or C(S)NR5R6, then R5R6 together with the nitrogen may form a heterocyclic ring; or a pharmaceutically acceptable salt or solvate thereof.